Crispr Therapeutics is trading 5.7% higher in pre-market at $60.59, versus the October 5 close of $57.34; no October 6 company announcement explaining the move was found.
- The latest listed company release, dated October 2, announced a planned clinical-data presentation on Zugo-cel at ACR Convergence 2026.
- The S&P 500, Nasdaq Composite, and Dow were all higher, but none gained more than 0.5%. Available evidence does not establish that market sentiment or the earlier announcement caused the move.